Esperion Therapeutics has been granted a patent for methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and pharmaceutical materials containing it. The invention also covers treating diseases using these compositions. GlobalData’s report on Esperion Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Esperion Therapeutics, NSAID cancer drugs was a key innovation area identified from patents. Esperion Therapeutics's grant share as of May 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for method of preparing pharmaceutical material
A recently granted patent (Publication Number: US11987548B2) outlines a method for preparing a pharmaceutical material containing a specific compound of formula (V). The method involves several steps, including the use of specific molar ratios and reagents to ensure the formation of the desired compound. For instance, the method specifies the use of sodium iodide as a salt in one step and the precise molar ratios of various compounds in different stages of the process. The patent also includes purification steps to ensure the final product contains a high percentage of the compound of formula (V), with purity levels exceeding 99.0% by weight.
Furthermore, the patent details additional steps for further purifying the compound of formula (V) to achieve a pharmaceutical material with exceptional purity levels. These steps involve adjusting the pH of the solution, extracting the compound using specific solvents, and conducting crystallization and recrystallization processes. The patent emphasizes the importance of maintaining specific temperature ranges during these purification steps to ensure the formation of a crystalline form of the compound. The final pharmaceutical material obtained through this method contains a purified amount of the compound of formula (V) exceeding 99.0% by weight, meeting high-quality standards for pharmaceutical products.
To know more about GlobalData’s detailed insights on Esperion Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
